Participation in any investigational drug study (excluding non-oncology and/or symptom management studies) within 4 weeks prior to registration.
Participation in other studies involving investigational drug(s) within 28 days prior to study entry.
Participation in other clinical trials within at least 2 weeks of the first ORH-2014 dose;
Prior participation in a clinical study of viagenpumatucel-L
Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
Participation in any study involving administration of an investigational agent within 30 days of randomization into this study
Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
Previous participation in a clinical study of IV or oral rigosertib; patients who failed screening for other rigosertib studies may be screened for participation
Concurrent participation in other investigational drug trials.
Prior participation in an investigational study within 21 days of study day 1
Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation
Current participation in another research or observational study.
Current participation in or previous participation in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment
Participation in other studies involving investigational drug(s) (phases 1-4) within 2 weeks before randomization in the current study
Participation to a study involving a medical or therapeutic intervention in the last 30 days
Prior participation in this study
Patients treated on any other therapeutic clinical protocols within 10 days prior to registration or during participation in the study
Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
Participation in a clinical study involving receipt of an investigational drug during the last 30 days.
Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
Subjects with leukemia are not eligible for study participation
Discontinued study participation in Verastem-sponsored IPI-145-07 study
Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation;
Any other investigational treatments within 4 weeks prior to and during study; includes participation in any medical device or other therapeutic intervention clinical trials
Current participation in another clinical study of an investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable after sponsor approval.
Participation in a prior investigational study within 30 days prior to enrollment
Participation in any previous study involving sipuleucel-T
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
agree to take a pregnancy test prior to starting study medication and throughout the study participation.
Females must abstain from breastfeeding during study participation and 3 months after IP discontinuation.
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
Current or recent treatment with another investigational drug within 30 days of first study treatment dosing or earlier participation in this study
Concurrent participation in any other investigational study
Participation in the active phase of other clinical trials of investigational agents in which last study treatment was administered within 2 weeks prior to randomization
Participation in another research study involving an investigational agent within 30 days prior to consent or projected study participation during the 28 days post study randomization.
Women must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from protocol treatment
Participation in a therapeutic research study or receipt of an investigational drug within 4 weeks of leukapheresis
Participation in any other clinical investigation within 4 weeks of receiving the first dose of study drug
Participation in any other research protocol involving administration of an investigational agent within 6 weeks prior to study entry
Participation in an investigational anti-cancer study within 3 weeks prior to day -7 (beginning of loading phase)
Participation in any other investigational drug study within 4 weeks of study enrollment
Participation in other studies involving investigational drug(s) within 4 weeks prior to study participation and/or during study participation.
Participation in concurrent investigational studies
Participation in an investigational therapeutic study within 3 weeks prior to first dose
Current participation in other clinical study
Participation in any clinical study or having taken any investigational therapy within 28 days.
participation in other investigational studies, unless approved in writing by the study sponsor.
current participation in other clinical study
Participation in other studies involving investigational drug(s) (Phases 1-4) within 4 weeks of registering for the current study and/or during study participation.
Participation in other studies involving investigational drug(s) (Phases 1-4) before the current study begins and/or during study participation.
Participation in clinical drug trials within 4 weeks
Participation in a therapeutic research study or receipt of an investigational drug within 30 days of T-cell infusion
Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 2 weeks prior to treatment in this study
Female patients may not be breastfeeding at screening and must not breastfeed during study participation through 45 days after the last dose of study drug.
Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study
Previous participation in a clinical study of Kevetrin
Participation in another clinical study with an investigational drug within 30 days of Screening.
Participated in any previous study of aprepitant or fosaprepitant, or taken an investigational drug within 4 weeks prior to study participation
Current participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatment
Current participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatment
Females must agree to abstain from breastfeeding during study participation and 28 days after study drug discontinuation
Participation in an investigational therapeutic study within 14 days of initiation of study drug treatment
Likely to continue to need treatment of OIC for the duration of participation in the study.
Participation in a study with an investigational drug from 4 weeks prior to study start until study end
Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
Participation in any other clinical study within the last 4 weeks prior to the start of the study
Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of the study drug.
Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.
(Physician participation) seeing the patient in consultation on the day of the study
Participation in a therapeutic research study within 30 days of baseline
Concomitant participation in any other investigational treatment study; simultaneous participation in non-therapeutic or observational studies will not be an exclusion criterion
Declined participation in the study
Approval of Oncology provider for participation in this study
Participation in any other investigational treatment within the 6 weeks prior to enrollment or concurrent with this study.
Prior participation, i.e., receipt of study medication, in this study;
Participation in another clinical study within 28 days of the day chemotherapy is initiated, in which the study drug or device may influence hematopoiesis. Co-enrollment in another study is allowed in cases where the investigational therapy under study is a version of an acceptable chemotherapy regimen for this study per the inclusion criteria.
Previous participation in this study
Participation in another research project that might interfere with completion of this study
Medical clearance from treating clinician for study participation
Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study
Participation in other research protocols does not exclude a patient from participation in this study
Participation in any other study in last 30 days
Participation in other clinical study within the last 30 days
Patient has completed participation in another clinical study involving administration of an investigational agent in the preceding 4 weeks. However, participation in clinical studies involving other investigational PET or SPECT tracers will not be excluded if in the opinion of the Investigator:
Participation in more than 3 research studies in the past 6 months. Participation in a smoking study in the past 6 months. Participation in a study which involved medication within the last month
